176 related articles for article (PubMed ID: 18683094)
1. Tetrathiomolybdate, a copper chelator for the treatment of Wilson disease, pulmonary fibrosis and other indications.
Medici V; Sturniolo GC
IDrugs; 2008 Aug; 11(8):592-606. PubMed ID: 18683094
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease.
Brewer GJ; Askari F; Lorincz MT; Carlson M; Schilsky M; Kluin KJ; Hedera P; Moretti P; Fink JK; Tankanow R; Dick RB; Sitterly J
Arch Neurol; 2006 Apr; 63(4):521-7. PubMed ID: 16606763
[TBL] [Abstract][Full Text] [Related]
3. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study.
Brewer GJ; Dick RD; Grover DK; LeClaire V; Tseng M; Wicha M; Pienta K; Redman BG; Jahan T; Sondak VK; Strawderman M; LeCarpentier G; Merajver SD
Clin Cancer Res; 2000 Jan; 6(1):1-10. PubMed ID: 10656425
[TBL] [Abstract][Full Text] [Related]
4. Tetrathiomolybdate in the treatment of acute hepatitis in an animal model for Wilson disease.
Klein D; Arora U; Lichtmannegger J; Finckh M; Heinzmann U; Summer KH
J Hepatol; 2004 Mar; 40(3):409-16. PubMed ID: 15123354
[TBL] [Abstract][Full Text] [Related]
5. Tracing copper-thiomolybdate complexes in a prospective treatment for Wilson's disease.
Zhang L; Lichtmannegger J; Summer KH; Webb S; Pickering IJ; George GN
Biochemistry; 2009 Feb; 48(5):891-7. PubMed ID: 19146437
[TBL] [Abstract][Full Text] [Related]
6. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
7. WTX101 - an investigational drug for the treatment of Wilson disease.
Weiss KH; Członkowska A; Hedera P; Ferenci P
Expert Opin Investig Drugs; 2018 Jun; 27(6):561-567. PubMed ID: 29806946
[TBL] [Abstract][Full Text] [Related]
8. Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson disease.
Kirk FT; Munk DE; Swenson ES; Quicquaro AM; Vendelbo MH; Larsen A; Schilsky ML; Ott P; Sandahl TD
J Hepatol; 2024 Apr; 80(4):586-595. PubMed ID: 38081365
[TBL] [Abstract][Full Text] [Related]
9. Drug evaluation: (R)-flurbiprofen--an enantiomer of flurbiprofen for the treatment of Alzheimer's disease.
Geerts H
IDrugs; 2007 Feb; 10(2):121-33. PubMed ID: 17285465
[TBL] [Abstract][Full Text] [Related]
10. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors.
Choueiri TK
Curr Opin Investig Drugs; 2008 Jun; 9(6):658-71. PubMed ID: 18516765
[TBL] [Abstract][Full Text] [Related]
11. Status epilepticus in Wilson's disease.
Pestana Knight EM; Gilman S; Selwa L
Epileptic Disord; 2009 Jun; 11(2):138-43. PubMed ID: 19473947
[TBL] [Abstract][Full Text] [Related]
12. Novel perspectives on Wilson disease treatment.
Rupp C; Stremmel W; Weiss KH
Handb Clin Neurol; 2017; 142():225-230. PubMed ID: 28433106
[TBL] [Abstract][Full Text] [Related]
13. Carisbamate, a new carbamate for the treatment of epilepsy.
Kulig K; Malawska B
IDrugs; 2007 Oct; 10(10):720-7. PubMed ID: 17899491
[TBL] [Abstract][Full Text] [Related]
14. Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.
Brewer GJ; Merajver SD
Integr Cancer Ther; 2002 Dec; 1(4):327-37. PubMed ID: 14664727
[TBL] [Abstract][Full Text] [Related]
15. Varespladib methyl, an oral phospholipase A2 inhibitor for the potential treatment of coronary artery disease.
Karakas M; Koenig W
IDrugs; 2009 Sep; 12(9):585-92. PubMed ID: 19697278
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic evaluation of ammonium tetrathiomolybdate after intravenous and oral administration to healthy dogs.
Chan CM; Langlois DK; Buchweitz JP; Lehner AF; Olivier NB; Herdt TH; Bailie MB; Schall WD
Am J Vet Res; 2015 May; 76(5):445-53. PubMed ID: 25909377
[TBL] [Abstract][Full Text] [Related]
17. AEG-35156, an antisense oligonucleotide against X-linked inhibitor of apoptosis for the potential treatment of cancer.
Tamm I
Curr Opin Investig Drugs; 2008 Jun; 9(6):638-46. PubMed ID: 18516763
[TBL] [Abstract][Full Text] [Related]
18. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
19. SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers.
Mills DA; Fekrazad HM; Verschraegen CF
Curr Opin Investig Drugs; 2008 Jun; 9(6):647-57. PubMed ID: 18516764
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors.
Lowndes SA; Adams A; Timms A; Fisher N; Smythe J; Watt SM; Joel S; Donate F; Hayward C; Reich S; Middleton M; Mazar A; Harris AL
Clin Cancer Res; 2008 Nov; 14(22):7526-34. PubMed ID: 19010871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
